Movement Alert｜METIS TECHBIO-P falls 5.28% in Regular Trading, UBS downgrade and post-deal divergence weigh on sentiment

Market Focus10-23 09:37

On October 23, METIS TECHBIO-P fell 5.28% in Regular Trading, trading at HK$10.12, with turnover of HK$6.63 million.

The latest identifiable catalyst is an event-driven mix of a broker rating change and continued investor divergence after the company’s previously announced Lilly collaboration.

Recent market reports indicate UBS downgraded METIS TECHBIO-P to neutral, while the market continues to reassess valuation and commercialization timing following the company’s strategic cooperation with Eli Lilly on next-generation tissue-specific LNP delivery technology. Under the disclosed terms, the company is eligible for an upfront payment in the low double-digit millions of US dollars, up to about US$1.1 billion in development, regulatory and commercial milestones, and single-digit tiered royalties. While the Lilly deal reinforced platform validation for its AI-driven AiLNP technology, recent trading suggests the initial optimism has given way to profit-taking and a more divided view on near-term value realization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment